MedTrace Logo

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

NCT06125028 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-04-28

No results posted yet for this study

Summary

This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission tomography (PET) imaging agent \[68Ga\]Ga-PTF) , versus \[18F\]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma exemplary for CXCR4-positive malignant lymphomas.

Conditions

Interventions

DRUG

[68Ga]Ga-PentixaFor

\[68Ga\]Ga-PTF i.v. injection

DRUG

[18F]Fluorodeoxyglucose

\[18F\]FDG i.v. injection.

Sponsors & Collaborators

  • Pivotal S.L.

    collaborator INDUSTRY

  • Pentixapharm AG

    lead INDUSTRY

Principal Investigators

  • Andreas Buck, Prof. Dr. · University Hospital Würzburg, Department of Nuclear Medicine

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2025-07-18
Completion
2025-07-18

Countries

  • Austria
  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06125028 on ClinicalTrials.gov